| Prev Close | 3.83 |
| Open | 3.81 |
| Day Low/High | 3.77 / 3.85 |
| 52 Wk Low/High | 2.96 / 25.60 |
| Volume | 1.08M |
| Avg Volume | 2.01M |
| Exchange | NASDAQ |
| Shares Outstanding | 100.55M |
| Market Cap | 374.03M |
| EPS | -1.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Celldex Therapeutics (CLDX) Stock Up on Q2 Results
Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.
Celldex Therapeutics (CLDX) Is Strong On High Volume Today
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
Celldex Reports Second Quarter 2016 Results
Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time
Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call
Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time
Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma
Antibody-drug conjugate directed to TIM-1, a novel target upregulated in several cancers
Celldex Therapeutics (CLDX) In A Perilous Reversal
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate
Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma
CDX-301's utility as a dendritic cell growth factor in combination therapy established
Immunomedics Kicked Out of Prestigious ASCO Cancer Conference
Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting.
Celldex Therapeutics (CLDX): Today's Weak On High Volume Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate
Great Breadth Fails to Counter Boring Market
This, despite a rare 10-point jump in bulls in the Investors Intelligence readings, which usually occurs in bear markets.
6 Breakout Stocks Under $10 Set to Soar
These stocks trading for less than $10 a share are within range of triggering breakout trades.
Commit To Buy Celldex Therapeutics At $3, Earn 30% Using Options
Investors eyeing a purchase of Celldex Therapeutics, Inc. shares, but tentative about paying the going market price of $4.21/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Celldex Therapeutics (CLDX) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate
Celldex Therapeutics (CLDX) Weak On High Volume
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a weak on high relative volume candidate
Short Interest In Celldex Therapeutics Increases 12%
The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 2,772,151 share increase in total short interest for Celldex Therapeutics, Inc. , to 25,763,736, an increase of 12.06% since 03/15/2016.
Anavex Plays the Orphan Drug Stock Promotion Game
Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Perilous Reversal" Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's Strong On High Relative Volume Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
7 Stocks Under $10 to Trade for Breakout Gains
These stocks trading for less than $10 a share are within range of triggering big breakout trades.
Celldex Therapeutics (CLDX) Highlighted As Today's Perilous Reversal Stock
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate
6 Biotech Stocks Under $10 to Trade for Big Breakouts
These stocks trading for less than $10 a share are within range of triggering big breakout trades.
